Literature DB >> 2910538

Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology.

E K van den Berg1, J M Schmitz, C R Benedict, C R Malloy, J T Willerson, G J Dehmer.   

Abstract

Serotonin is released by activated platelets and may act as a mediator to initiate or sustain certain unstable syndromes of ischemic heart disease in humans. To determine whether or not serotonin concentration increases across the coronary bed in patients with severe, limiting angina, we measured central aortic and coronary sinus serotonin concentrations by a sensitive radioenzymatic assay in 39 patients with coronary artery disease and 13 patients with minimal or no coronary artery lesions as detected by arteriography. Although no difference existed in the mean aortic or coronary sinus serotonin concentrations between these two groups, elevated coronary sinus serotonin concentrations were detected in 23% of those with coronary artery disease. The coronary sinus and aortic serotonin concentration difference was greater in patients with significant coronary artery disease (0.6 +/- 6.62 ng/ml) compared with patients without significant coronary artery disease (-5.6 +/- 10.32 ng/ml) (mean +/- SD) (p less than 0.05). Further analysis revealed that patients with eccentric, irregular coronary artery lesions or intraluminal filling defects had a significantly elevated coronary sinus and aortic serotonin difference (3.1 +/- 5.54 ng/ml) compared with those with smooth concentric lesions (-1.9 +/- 6.61 ng/ml) (p less than 0.02). These data suggest that serotonin is released into the coronary circulation of some patients with coronary artery disease, especially those with frequent angina and complex coronary lesions. Although serotonin may be released in some patients with coronary artery disease, the specific pathophysiologic role of serotonin in the development or perpetuation of certain coronary syndromes in humans remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910538     DOI: 10.1161/01.cir.79.1.116

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  Effect of the thromboxane A2-mimetic U46619 on 5-HT1-like and 5-HT2 receptor-mediated contraction of the rabbit isolated femoral artery.

Authors:  S J MacLennan; G R Martin
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

Review 2.  Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels.

Authors:  Charles P Mercado; Fusun Kilic
Journal:  Mol Interv       Date:  2010-08

3.  Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT(3) receptors.

Authors:  Liang-Wu Fu; John C Longhurst
Journal:  J Physiol       Date:  2002-11-01       Impact factor: 5.182

4.  Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin.

Authors:  Endrit Ziu; Charles P Mercado; Yicong Li; Preeti Singh; Billow A Ahmed; Samuel Freyaldenhoven; Shelly Lensing; Jerry Ware; Fusun Kilic
Journal:  J Mol Cell Cardiol       Date:  2012-02-15       Impact factor: 5.000

5.  Role of 5-HT3 receptors in activation of abdominal sympathetic C fibre afferents during ischaemia in cats.

Authors:  L W Fu; J C Longhurst
Journal:  J Physiol       Date:  1998-06-15       Impact factor: 5.182

Review 6.  Serotonin: a different player in hypertension-associated thrombosis.

Authors:  Mony Fraer; Fusun Kilic
Journal:  Hypertension       Date:  2015-03-09       Impact factor: 10.190

7.  Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts.

Authors:  Tatsuya Muto; Yoshihiro Hotta; Kunihiro Miyazeki; Hiroaki Ando; Naohisa Ishikawa; Takaaki Hasegawa; Yumi Sugimoto; Jun Yamada; Yasuyoshi Miki
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

8.  5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo.

Authors:  F De Clerck; W Loots; Y Somers; J Beetens; L Wouters; J Wynants; P A Janssen
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

9.  Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.

Authors:  P R Belcher; A J Drake-Holland; J W Hynd; M I Noble
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 10.  Endothelial dysfunction and atherothrombotic occlusive disease.

Authors:  J E Freedman; J Loscalzo
Journal:  Drugs       Date:  1997       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.